VAC2VAC

Vaccine lot to vaccine lot comparison by consistency testing

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 3
Grant agreement number
115924

Contributions
IMI Funding
7 850 001
EFPIA in kind
8 128 429
Other
312 500
Total Cost16 290 930

Summary

Developing and validating alternative, non-animal testing approaches for both human and veterinary vaccines is the main goal of the VAC2VAC project. In routine vaccine production, the current quality control approach requires large numbers of laboratory animals. VAC2VAC aims to provide data to support the ‘consistency approach’ for quality control that promotes the use of in vitro, analytical, non-animal based systems. The project brings together scientists from both the human and veterinary pharmaceutical industry along with academia and regulators. Together they plan to develop and validate non-animal tests; generate vaccine specific toolkits of consistency tests; increase our scientific understanding of vaccine quality; and contribute to the regulatory acceptance and routine use of non-animal tests during vaccine quality control testing.

Participants Show participants on map

EFPIA companies
  • Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein, Germany
  • GlaxoSmithKline Biologicals S.A, Rixensart, Belgium
  • Intervet International BV, Boxmeer, Netherlands
  • Merial S.A.S, Lyon, France
  • Sanofi Pasteur, Lyon, France
  • Zoetis Belgium SA , Louvain la Neuve, Belgium
Universities, research organisations, public bodies, non-profit groups
  • (UK) Department of Health, Leeds, United Kingdom
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Association Internationale De Standardisation Biologique Pour L'Europe (IABS-EU), Lyon, France
  • Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany
  • European Commission - Directorate General Joint Research Centre - JRC, Brussels, Belgium
  • European Vaccine Initiative - EEIG, Heidelberg, Germany
  • Foundation BIOMEDICAL PRIMATE RESEARCH CENTRE, Rijswijk, Netherlands
  • Institut Scientifique De Sante Publique, Brussels, Belgium
  • Institute for Translational Vaccinology part of the Ministerie van volksgezondheid, welzijn en sport, Bilthoven, Netherlands
  • Istituto Superiore Di Sanita', Roma, Italy
  • Rijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment), Bilthoven, Netherlands
  • Stichting Hogeschool Utrecht, Utrecht, Netherlands
  • Universiteit Utrecht, Utrecht, Netherlands
  • agentschap College ter Beoordeling van Geneesmiddelen, Utrecht, Netherlands
  • Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH, Vienna, Austria

CONTACT

Project coordinator
Odile Leroy
EUROPEAN VACCINE INITIATIVE - EEIG
odile.leroy[at]euvaccine.eu
EFPIA coordinator
Sylvie Uhlrich
Sanofi Pasteur
Sylvie.Uhlrich[at]sanofipasteur.com